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tient stay were linked. Their overall survival data were presented as product-limit 
survival probabilities. Results: There were 240 to 290 new cases annually between 
2006 and 2011. The raw incidence rate was about 1.1 to 1.26 per 100,000 persons,. 
The age adjusted incidence rate was around 1.5 per 100,000 persons. This was much 
lower than that the overall incidence in the US (21.1 per 100,000 per year). But it was 
similar to that of Asia-Pacific islanders in the US. The proportion of death between 
2006 and 2011 were 28.8% and 21.9% among males and females respectively. This 
was different from the US population, whose 5 year survival was 91.3%. The popula-
tion composition of the US was different from that in Taiwan and thus cannot be 
compared directly. About 29% of Taiwan patients were farmers. The mortality of 
farmers (36.5%) was slightly higher than that of non-farmers (22.4%). After control-
ling for age and sex, the hazard ratio of farmer vs. non-farmers was 1.136. Their age 
of diagnosis was much higher than the non-farmers: 82% and 34% for farmers and 
non-farmers diagnosed at age 65 and above, respectively. ConClusions: Malignant 
melanoma is found to be a rare but deadly disease in Taiwan. One reason for low 
survival probability was that farmers delayed the diagnosis to old age. It is suggested 
to screen farmers in early age.
PCN47
HOW SINGLE ARM PHASE II DATA CAN SUPPORT REIMBURSEMENT FOR 
ONCOLOGICS IN AUSTRALIA
Macaulay R
HERON Commercialization, London, UK
objeCtives: The Food and Drug Administration (FDA) have approved 28 oncolog-
ics across 37 indications on the basis of pivotal Phase II data lacking an active 
comparator (Macaulay, ISPOR Toronto 2014). Approval was typically granted for 
indications with therapeutic alternative where a response rate ≥ 10% was demon-
strated. This research aims to define the circumstances under which oncologics 
can obtain both regulatory approval and public reimbursement in Australia on this 
basis. Methods: Public Summary Documents (PSDs) were extracted for any onco-
logic indication appraised by the FDA on pivotal Phase II data and the Therapeutic 
Goods Administration (TGA) and Pharmaceutical Benefits Advisory Committee 
(PBAC) decision and key rationale were extracted. Results: 3 oncologics across 7 
oncology indications (nilotinib in chronic myelogenous leukemia, dasatinib in acute 
lymphoblastic leukaemia (ALL), imatinib in ALL, dermatofibrosarcoma protuberans, 
myelodysplastic syndrome/ myeloproliferative disease and hypereosinophilic syn-
drome and/or chronic eosinophilic leukemia, and aggressive mastocytosis) have 
been granted TGA and PBAC approval on pivotal Phase II data. 2 were TGA approved 
but PBAC rejected (bevacizumab and cetuximab), 3 were submitted to PBAC on 
Phase III data, and no PSDs were extractable for the remaining 26 indications. In 
7/7 approved indications, PBAC recognized active comparator alternatives. In 4/7, 
the rarity of these indications was cited as a key mitigating factor. For 2/7, overall 
survival (OS) data was presented that indicated potentially substantial OS benefits. 
In 1/7, a cost-minimisation argument was accepted against a recently approved 
comparator. Of the PBAC-rejected drugs, cetuximab raised key concerns over a lack 
of OS data, while significant trial comparability issues were expressed with beva-
cizumab. All PBAC-approved submissions included economic modelling on a cost/
benefit, not cost/QALY, approach. ConClusions: PBAC can recommend the reim-
bursement of oncologics that offer potentially substantial clinical benefits based 
on an indirect comparison of single arms trials with acceptable cost-effectiveness 
as demonstrated on a cost-benefit metric.
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QUALITy CONTROL OF THE HUNGARIAN NATIONWIDE MAMMOGRAPHy 
SCREENING PROGRAMME
Boncz I1, Endrei D1, Ágoston I1, Vajda R1, Csákvári T2, Kovács G3, Sebestyén A4
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István 
University, Győr, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary
objeCtives: Organised, nationwide screening for breast cancer with mammogra-
phy in the age group 45-65 years with 2 years screening interval started in Hungary 
in January 2002. According to the Hungarian guideline on mammography screening, 
an accredited mammography screening centre should perform 10000 examinations 
annually. The aim of this study is to analyze the quality control indicators of this 
screening programme. Methods: The data derive from the financial database of 
the National Health Insurance Fund Administration (NHIFA) covering the period 
2002-2010 year. We analysed 3 selected years: 2002, 2005 and 2010. The main indica-
tor was the number of mammography screening examinations performed by the 
mammography screening centres. Results: The annual number of mammography 
examinations was 323537 in 2002, 247045 in 2005 and 242601 in 2010. The number 
of accredited mammography screening centres were 51 (2002), 41 (2005) and 40 
(2010). The average number of mammography examinations were 6344 (2002), 6025 
(2005) and 6065 (2010) per year. In 2002, 14 mammography centres performed 10000 
examinations in a range from 10314 to 25940. In 2005 only 4 mammography centres 
achieved more than 10000 examinations per year (range: 10294-17845). In 2010 again 
only 4 mammography centres achieved more than 10000 examinations per year 
(range: 10239-19259). ConClusions: Only a few number of mammography centres 
met the recommendation of the Hungarian mammography screening guideline 
and reached the target (10000 mammography examinations annually). Most of the 
mammography centres are not able to comply with professional guideline.
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
INCRETIN THERAPy AND RISk OF PANCREATITIS IN TyPE 2 DIABETES 
MELLITUS: SySTEMATIC REvIEW OF RANDOMIzED AND NON-RANDOMIzED 
STUDIES
Li L1, Shen JT2, Bala MM3, Busse JW4, Ebrahim S4, Vandvik PO5, Rios LP6, Malaga G7, Wong 
E8, Sohani Z4, Guyatt GH4, Sun X1
vitro dissolution study in three different solvents such as hydrochloric acid pH 1.5, 
artificial saliva pH 6.7 and saline phosphate buffer solution pH 7.4 respectively. And 
drug release from the in vitro dissolution study. Results: The result reveals that 
prepared formulation F6 shown maximum value. The ex vivo permeation studies 
of Fluconazole drug through porcine buccal mucous membrane were performed 
and the results shown that F6 formulation was the best formulation among the 
prepared mouth dissolving tablets. ConClusions: Thus, the prepared (F6 formula-
tion) mouth dissolving tablets had both local and systemic action and may be used 
for treating oropharyngeal and esophageal candidiasis (oral candidiasis) mainly as 
ulcer, burning sensation of buccal cavity particularly in premature infants, geriatric 
bed ridden patients, and patients with weak immune system caused by cancer 
treatment or diseases such as AIDS.
PCN44
TIME TO REIMBURSEMENT FOR ONCOLOGy AGENTS FROM EMA MARkETING 
AUTHORIzATION TO AIFA APPROvAL AS “C(NN)” CLASS vERSUS. AIFA 
APPROvAL AS “A” OR “H” CLASS
Monoson L1, Martin de Bustamante MA2, Beckerman R1
1CBPartners, New York, NY, USA, 2CBPartners, San Francisco, CA, USA
objeCtives: The purpose of this study was to evaluate the reduction in average 
market entry timelines for oncology agents in Italy if approved by AIFA as “C(nn)” 
class (non-negotiated class under the 189/2012 law) as compared to “A” (fully reim-
bursed) / “H” (hospital reimbursement). Methods: For the purpose of this study, 
only the approval of the agents’ first indications were taken into consideration. 
Included in this study were C(nn) oncology agents approved between May 27, 2013 
and February 27, 2014 (aflibercept, pertuzumab, bosutinib, enzalutamide, vismo-
degib, pomalidomide, regorafenib, dabrafenib, infliximab, afatinib, radium Ra223 
dichloride, trastuzumab emtansine) and class “A” / “H” agents approved between May 
27, 2010 and December 2, 2013 (everolimus®, denosumab, pazopanib, cabazitaxel, 
denosumab, abiraterone, vemurafenib, vandetanib, axitinib). The average time to 
approval was calculated as the average difference between the date of issue of EMA 
marketing authorization and the determination date (“determina”) in the Italian 
“Gazzetta Ufficiale”. Results: The average time to reimbursement for oncology 
agents from EMA marketing authorization to AIFA approval as “C(nn)” class was 
estimated as 111.3±39.9 days (n= 12), while the average time to reimbursement as 
either “A” or “H” class was estimated as 428.3±109.0 days (n= 9). This represents a 
significantly faster approval process (unpaired t-test, p< 0.01), where on average, the 
C(nn) approval process is faster by 317 days. ConClusions: This study shows that 
time to reimbursement for oncology agents from EMA marketing authorization to 
AIFA approval is significantly expedited through the use of “C(nn)” classification, 
reducing market entry timelines by nearly a full year (317 days) compared to the 
regular “A” or “H” class approval process. Pharmaceutical companies seeking expe-
ditious market entry into Italy for a newly approved oncology therapy targeting an 
area of high unmet need should therefore consider applying for C(nn) class.
PCN45
COvERAGE DECISION FRAMEWORk IN ASIA PACIFIC: A CASE STUDy OF 
TARGETED CANCER MEDICINES IN THE TREATMENT OF BREAST CANCER
Sruamsiri R1, Chaiyakunapruk N2, Leartsakulpanitch J3
1Naresuan University, muang, Thailand, 2Monash University Malaysia, Selangor, Malaysia, 
3Janssen Asia Pacific, Singapore
objeCtives: To optimize access to cancer therapy in Asia Pacific (AP) nowadays 
became challenging due to budget constraints. Different decisions were made due 
to individual context, health care system and evidence required to support the 
decision. This study reviewed coverage decisions made by government in AP using 
targeted cancer medicines as a case study. Methods: We selected 6 targeted cancer 
medicines recommended for breast cancer treatment based on the 2013 national 
comprehensive cancer network guidelines. Eight AP countries with different health 
coverage system were included to highlight the differences of health coverage sys-
tem on decisions: four reimbursement countries [Australia (AUS), South Korea (KE), 
Taiwan (TW) and Japan (JP)] and four partial reimbursement countries [Malaysia 
(MY), Thailand (TH),China (CN) and Hong Kong (HK)]. We identified data from mul-
tiple sources including “Pubmed”, government websites, payers and companies 
from inception till Jan 2014. We compared health coverage features, oncology cov-
erage list and evidence requirement for decision making. Based on HTA approach, 
six possible supporting factors were compared. They included burden of disease, 
clinical effectiveness, economic evaluation (EE), budget impact analysis (BIA), public 
health impact, ethical concern and availability of alternative treatments. Results: 
Efficacy and safety data were used as decision factors in all countries. AUS, KE, TW 
and TH considered both EE and BIA. AUS, KE and TH required local HTA evidence 
.Of six medicines, trastuzumab is now covered in most countries: AUS, MY, TW 
and KE. However, limited information is publicly available on evidence used in 
coverage decision in most countries except AUS where all factors except public 
health impact and ethical issue consideration are documented. ConClusions: 
Coverage decisions are affected by health care system and HTA evidence. Limited 
public documents related to coverage decisions are available. HTA system may lead 
to the development of explicit decision framework criteria for coverage decisions.
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THE INCIDENCE, PREvALENCE, AND SURvIvAL OF MALIGNANT MELANOMA IN 
TAIWAN
Chang HY1, Feng HL1, Wang L2, Chou P2, Wang PF3
1National Health Research Institutes, Maoli county, Taiwan, 2Bristol-Myers Squibb, Taipei, Taiwan, 
3Bristol-Myers Squibb, Lawrenceville, NJ, USA
objeCtives: To understand the incidence, prevalence, and survival probability in 
the whole population in Taiwan. Methods: This study utilized the 2005 to 2011 
National Health Insurance (NHI) Research Database to study the disease. Inclusion 
criterion was that patients had at least two outpatient visits or one inpatient stay for 
melanoma (ICD9 code: 172). Patients’ medical orders for outpatient visits and inpa-
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A741
PDB4
EFFICACy OF ADD – ON vILDAGLIPTIN THERAPy TO METFORMIN FOR TyPE 
II DIABETES MELLITUS PATIENTS IN SOUTH INDIAN RESOURCE LIMITED 
SETTINGS – PILOT STUDy
Vigneshwaran E1, Venkatesh K1, Kirankumar C1, Rubiya S1, Padmanabhareddy Y1,  
Achar B2
1raghavendra institute of pharmaceutical education and research, Anantapur, India, 2government 
medical college, Anantapur, India
objeCtives: Prevalence of diabetes mellitus is increasing globally in most developed 
and developing countries and Dipeptidyl peptidase-4 inhibitors (Gliptins) are recently 
introduced class of drugs for type 2 diabetes mellitus which shows good glycemic 
control. It is a prospective interventional pilot study aimed to determine the efficacy 
of add-on vildagliptin therapy to metformin in type 2 diabetes mellitus patients for 
a period of 6 months in south Indian resource limited settings. Methods: A total 
of 185 patients were enrolled into the study. The study subjects were assigned into 
three groups based on their existing treatment (initiated within one month) i.e., group 
I (vildagliptin and metformin), group II (vildagliptin alone) and group III (metformin 
alone). They were also assessed for baseline demographic characteristics. Medication 
adherence was measured to ensure that patients are complies with the treatment. 
The clinical endpoint was estimated by using various variables like quality of life and 
other clinical endpoints such as RBS, PPBS after three months of specific treatment 
through direct interview and by referring the medical case records. Results: The 
results show that there is no significant difference in individual groups in terms of 
demographic characteristics. (P > 0.01). And all the present study subjects are found to 
have more than 90 % of medication adherence. We observed high level of significant 
improvement in group I (93.18±3.76) subjects whereas low level of improvement in 
group III subjects (90.4±4.13) after the relevant treatment (P = 0.003). Group I subjects 
are also found to have good glycaemic control (RBS, FBS and PPBS) than any other 
treatment groups P< 0.01). ConClusions: Add on vildagliptin therapy to metformin 
might improve the quality of life of type 2 diabetes mellitus patients and might be 
useful to bring the glycemic levels under control in type 2 diabetic patients in South 
Indian resource limited settings.
PDB5
DIAGNOSTIC TESTS OF BLOOD GLUCOSE: A SySTEMATIC REvIEW
Haiyin W
Shang Health technology research CENTER, SHANGHAI, China
objeCtives: To evaluate the accuracy of different blood glucose determination meth-
ods, and provide a theoretical basis for governments to determine the mainstream 
glucose detection methods. Methods: The MEDLINE, EMBASE, EBM REVIEWS, CBM, 
CNKI, Wanfang, Google academic search et al were were retrieved for literatures col-
lection, literature quality evaluation was implemented by using QUADAS criteria, 
meta-analysis was carried out using Stata11.0 and heterogeneity test and sensitivity 
analysis was implemented. Results: 20 studies were included, which contained a 
total of 2681 cases of patients. Meta analysis showed that values measured by the 
dry chemical method were significantly higher than glucose oxidase method, and 
no significant differences was found with the hexokinase method, no significant 
differences was yet found between the electrode method with enzyme method, the 
MD (95%CI) were 0.31 (0.09, 0.53), -0.51 (-0.14, 1.17) and -0.13, (-0.27, 0.02) respectively. 
Sensitivity analysis of the model, the sample source, research population, equip-
ment and countries was carried out and conclusion was found no change between 
the methods. ConClusions: there was significant difference between different 
blood glucose detection methods; application of dry chemical measurement results 
should be cautious, we recommend using the glucose oxidase or diagnosis hexoki-
nase method.
PDB6
EFFECTIvENESS OF HERBOTRIM AND MUNIPRABHA IN THE MANAGEMENT OF 
HyPOTHyRODISM
Acharya S1, Mateti UV2, Nagappa AN2
1Muniyal Institute of Ayurveda Medical Sciences, Muniyal, India, 2Department of Pharmacy 
Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
objeCtives: Hypothroidism is treated by replacement therapy of levothyroxine in 
allopathic system of medicine needs to be taken through out life time. In Ayurveda 
an ethnic system of Indian medicine has a remedy based on the drugs of natural ori-
gin which showes improved thyroid function. In this study the patients are treated 
for Hypothroidism with combination of two proprietary medicines (Herbotrim and 
Muniprabha) of Muniyal Ayurveda Pharmacy, Manipal. Methods: Thirty cases 
Hypothyroidism are selected from Inpatients and Out patients of Muniyal Ayurveda 
Hospital, Manipal after obtaining the consent of the patients. The study was 
approved by intitutional ethics committe. The study design consited of observation 
before and after teatment with Herbotrim 2-0-2 (2 BID) with water and Muniprabha 
1-1-1 (1TID) with water, tablets along with concomitant medicines for a period of 
3 months. The subjective Obesity, Brady cardia, Somnolence, Slow mentationand 
objective criteria of assessment were T3, T4, TSH, Hb% and cholesterol. Results: 
The Mean palsma T3 (mcg/dl) levels were 33.4 to 105.4, T4 (mcg/dl) levels were 2.38 
to 11.36 and TSH (micro IU/ml) levels were109.4 to 6.63. The hemoglobin (g%) levels 
were increased from 10.05 to 12.24 and serum cholesterol (mg%) leveles were drop-
ded from 280 to 158.9. ConClusions: Considerable improvement was observed in 
both subjective and objective criteria of assessment. There was decrease in subjec-
tive criteria like – Obesity, Brady cardia, Somnolence, Slow mentation, etc. There 
was increase in T3 and T4, and nd Hb%. The decrease in TSH and cholesterol with 
Herbotrim and Muniprabha in Hypothyroidism patients.
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DESIGN & METHODS FOR STUDy OF PREvALENCE, RISk FACTORS AND 
ECONOMIC BURDEN OF INSULIN INjECTION-RELATED LIPOHyPERTROPHy IN 
CHINA
Tao L1, Chandran A2, Hirsch LJ2, Wei Z2, Wang D2, Ji L3, Sun Z4, Qin G5, LI Q6
1West China Hospital, Sichuan University, Chengdu, China, 2Huzhou Teachers College, Huzhou, 
China, 3Jagiellonian University School of Medicine, Krakow, Poland, 4McMaster University, 
Hamilton, ON, Canada, 5Norwegian Knowledge Centre for the Health Services, Oslo, Norway, 
6Hospital Clinico FUSAT, Rancagua, Chile, 7Universidad Peruana Cayetano Heredia, Lima, Peru, 
8University of British Columbia, Vancouver, BC, Canada
objeCtives: To examine the association between incretin-based therapies and 
the risk of pancreatitis. Methods: We searched Medline, Embase, CENTRAL and 
ClinicalTrials.gov to identify randomized controlled trials (RCTs), non-randomized 
clinical trials, cohort studies, and case-control studies of adults with type 2 diabe-
tes mellitus that compared glucagon-like peptide-1 (GLP-1) receptor agonists or 
dipeptidyl peptidase-4 (DPP-4) inhibitors against placebo or active anti-diabetic 
medications. Trained reviewers, working in pairs, independently screened for eli-
gible studies, assessed risk of bias, and extracted data. Results: We included 59 
studies (n= 348,624), consisting of 55 RCTs (n= 33,350) and 4 observational studies 
(n= 315,274). Pooled estimates of 55 RCTs (at low or moderate risk of bias involv-
ing 37 pancreatitis events, raw event rate 0.11%) did not suggest increased risk 
of pancreatitis between incretin agents versus control (Peto OR 1.11, 95% CI 0.57 
to 2.17). Estimates by type of incretin agents suggested similar results (GLP-1 
agonists vs. control: OR 1.05, 95% CI 0.37 to 2.94; DPP-4 inhibitors vs. control: 
OR 1.06, 95% CI 0.46 to 2.45). Three retrospective cohort studies (moderate to high 
risk of bias involving 1466 pancreatitis events, raw event rate 0.47%) also did not 
suggest increased risk of pancreatitis associated with either exenatide (adjusted 
OR 0.93, 95% CI 0.63 to 1.36 in one study, adjusted hazard ratio (HR) 0.9, 95% CI 
0.6 to 1.5 in another) or sitagliptin (adjusted HR 1.0, 95% CI 0.7 to 1.3). However, 
a matched case-control study with moderate risk of bias suggested that the use 
of either sitagliptin or exenatide was associated with increased odds of acute 
pancreatitis (adjusted OR 2.07, 95% CI, 1.36 to 3.13). ConClusions: The available 
evidence suggests that the risk of pancreatitis in patients using incretin agents 
is very low, and does not support for the hypothesis that incretins increase the 
risk of pancreatitis.
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EvALUATING THE EFFECTS OF ANTI-THyROID DRUGS AND THyROIDECTOMy 
IN PATIENTS RECEIvING RADIOACTIvE IODINE THERAPy FOR GRAvES’ 
HyPERTHyROIDISM - A RETROSPECTIvE STUDy FROM A UNIvERSITy 
TEACHING HOSPITAL IN SOUTH WEST, NIGERIA
Eniojukan JF1, Adepoju AO2
1Niger Delta University, Wilberforce Island, Nigeria, 2University College Hospital, Ibadan, Nigeria
objeCtives: This study evaluated the effect of anti-thyroid drugs and thyroid-
ectomy on response of hyperthyroidism to fixed doses of Radioactive Iodine 
Therapy (RAI) and the incidence of hypothyroidism at 6months post RAI ther-
apy. Methods: A retrospective review of the medical records of 42 hyperthyroid 
patients treated with radioiodine to evaluate response rate of hyperthyroidism 
to two fixed dose regimens of 370 MBq (10 mCi) and 555 MBq (15 mCi) RAI ther-
apy was carried out. The impacts of thyroidectomy and ant-thyroid drug pre-
treatment were documented. The treatment goal is to cure hyperthyroidism by 
rendering the patient either euthyroid or hypothyroid, within 6months of single 
dose of 370 MBq (10 mCi) or 555 MBq (15 mCi) RAI therapy. Statistical analysis was 
with SPSS version 15.0 and the level of statistical significance was taken as P < 
0.05. Results: The response (i.e. hypothyroid and euthyroid) at 6months post RAI 
for both doses of radioiodine was 71.4%, and after re-treatment of 7 patients who 
were earlier hyperthyroid after 6months, the response rate soared to 95.2%. The 
incidence of hypothyroidism (TSH > 6.1 mIU/L) was 47.6% with patients who had 
received 370 MBq (10 mCi) and 38.1% with those that received 555 MBq (15 mCi) 
radioiodine therapy. The use of anti-thyroid drugs (carbimazole or methima-
zole only) as pre-treatment increased response to RAI; Propylthiouracil however 
blocked response to RAI therapy in one patient Thyroidectomy, either total or 
subtotal, increased the response to RAI treatment. ConClusions: Radioactive 
iodine is highly effective for the treatment of Graves’ hyperthyroidism, with a very 
high cure rate. Pretreatment with some anti-thyroid drugs protects against wors-
ening of thyrotoxicosis after radioiodine and increases response to RAI therapy. 
Thyroidectomy increases the response to RAI treatment. However, the incidence 
of hypothyroidism should be anticipated and well prepared for as part of the 
treatment protocol.
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PREMIxED INSULIN LISPRO vERSUS INSULIN GLARGINE IN TyPE 2 DIABETES:  
A META-ANALySIS
Lili Z
CHINA PHARMACEUTICAL UNIVERSITY, nanjing, China
objeCtives: To systematically review the effectiveness and safety of premixed 
insulin lispro and insulin glargine in type 2 diabetes. Methods: Such databases as 
PubMed, EMBASE, The Cochrane Library, ClinicalTrials.gov, CBM, CNKI and WanFang 
were searched for relevant studies from inception to October, 2013. Two review-
ers independently screened studies according to exclusion and inclusion criteria, 
extracted data and assessed the methodological quality. Then, meta-analysis was 
performed using RevMan 5.2 software. Results: 13 RCTs involving 4267 patients 
were included. The results of meta-analysis showed that, compared to insulin 
glargine, premixed insulin lispro effectively improved HbA1c levels [WMD= -0.18, 
95%CI (-0.33, -0.02), P= 0.03(parallel trials), WMD= -0.38,95%CI(-0.52,-0.24), P< 0.00001 
(cross-over trials)]. However, insulin glargine effectively improved FPG levels 
[WMD= 0.82,95%CI(0.65, 0.99), P< 0.00001 (parallel trials)]; WMD= 0.64,95%CI(0.26, 
1.02), P= 0.0009 (cross-over trials)], weight gain[WMD= 0.93, 95%CI(0.31,1.56), 
P= 0.003 (parallel trials); WMD= 0.74, 95%CI(0.19,1.29), P= 0.009(cross-over trials)] 
and decrease hypoglycemia incidence[OR= 1.26, 95%CI(1.10, 1.45), P= 0,0007(paral-
lel trials), OR= 2.24, 95%CI(1.45, 3.46), P= 0.0003(cross-over trials)]. ConClusions: 
: Premixed insulin lispro and insulin glargine have different advantages in clinical 
efficacy. Doctors should select the appropriate insulin treatment according to the 
patient’s health condition and efficacy target.
